Novo Nordisk shares plummeted nearly 21% after the company cut its full-year sales and earnings outlook due to weak growth expectations for its Wegovy and Ozempic drugs in the U.S. The company also ...

AstraZeneca Plc reported better-than-expected sales and rising profit for the second quarter, spurred by its stable of cancer medicines and growth in the United States. Revenue climbed 12 percent to ...